Clinical Trial

Clinical Trial of Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This trial is a randomized, partially blinded, positively controlled phase I clinical study. A total of 160 persons aged 18-59 years, 1-5 years, 6-11 months and 2 months (60-89 days) will be recruited into the trial, and the enrollment will be done according to the progression of age groups, from the oldest to the youngest, and the initial safety assessment will be conducted on the 8th day after the first dose of vaccination for each age group, and the next group will be enrolled only after the safety is confirmed.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-09-29; most recent amendment 2025-07-28.
Status change: Recruiting → Active, Not Recruiting 2025-07-28
Status change: Not Yet Recruiting → Recruiting 2024-12-02
Trial Details
NCT Number NCT06621654
Lead Sponsor CanSino Biologics Inc.
Conditions Haemophilus Influenzae Type B Infection
Enrollment 160 participants
Start Date 2024-11-15
Primary Completion 2026-10 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2026-08-06